Jack Geduldig

Jack Geduldig

Auto-generated profile, based on publicly available information

Jack Geduldig

Department of Urology Icahn School of Medicine at Mount Sinai New York NY USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 December 2023 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
RRRifaquat Rahman
Rifaquat Rahman
LTLorenzo Trippa
Lorenzo Trippa
ELEudocia Q. Lee
Eudocia Q. Lee
IAIsabel Arrillaga-Romany
Isabel Arrillaga-Romany
GFGeoffrey Fell
Geoffrey Fell
PWPatrick Y. Wen
Patrick Y. Wen
PURPOSE: The Individualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT) is a phase II platform trial that uses response adaptive randomization and genomic profiling to efficiently identify novel therapies for phase III testing. Three initial experimental arms (abemaciclib [a cyclin-dependent kinase [CDK]4/6 inhibitor], neratinib [an epidermal growth factor receptor [EGFR]/human epidermal growth factor receptor 2 inhibitor], and CC-115 [a deoxyribonucleic acid–dependent protein kinase/mammalian target of rapamycin inhibitor]) were simultaneously evaluated against a common control arm. We report the results for each arm and examine the feasibility and conduct of the adaptive platform design. PATIENTS AND METHODS: Patients with newly diagnosed O6-methylguanine–DNA methyltransferase-unmethylated glioblastoma were eligible if they had tumor genotyping to identify prespecified biomarker subpopulations of dominant glioblastoma signaling pathways (EGFR, phosphatidylinositol 3-kinase, and CDK). Initial random assignment was 1:1:1:1 between control (radiation therapy and temozolomide) and the experimental arms. Subsequent Bayesian adaptive randomization was incorporated on the basis of biomarker-specific progression-free survival (PFS) data. The primary end point was overall survival (OS), and one-sided P values are reported. The trial is registered with ClinicalTrials.gov (identifier: NCT02977780 ). RESULTS: Two hundred thirty-seven patients were treated (71 control; 73 abemaciclib; 81 neratinib; 12 CC-115) in years 2017-2021. Abemaciclib and neratinib were well tolerated, but CC-115 was associated with ≥ grade 3 treatment-related toxicity in 58% of patients. PFS was significantly longer with abemaciclib (hazard ratio [HR], 0.72; 95% CI, 0.49 to 1.06; one-sided P = .046) and neratinib (HR, 0.72; 95% CI, 0.50 to 1.02; one-sided P = .033) relative to the control arm but there was no PFS benefit with CC-115 (one-sided P = .523). None of the experimental therapies demonstrated a significant OS benefit ( P > .05). CONCLUSION: The INSIGhT design enabled efficient simultaneous testing of three experimental agents using a shared control arm and adaptive randomization. Two investigational arms had superior PFS compared with the control arm, but none demonstrated an OS benefit. The INSIGhT design may promote improved and more efficient therapeutic discovery in glioblastoma. New arms have been added to the trial.

16 October 2024 in BJU International
Verified
Journal Article
Closed access
RBReuben Ben-David
Reuben Ben-David
SLSarah Lidagoster
Sarah Lidagoster
JGJack Geduldig
Jack Geduldig
KKKaushik P. Kolanukuduru
Kaushik P. Kolanukuduru
YEYuval Elkun
Yuval Elkun
JSJohn P. Sfakianos
John P. Sfakianos

11 May 2023 in BJU International
Verified
Journal Article
Closed access
JRJordan M. Rich
Jordan M. Rich
YEYuval Elkun
Yuval Elkun
JGJack Geduldig
Jack Geduldig
ELEtienne Lavallee
Etienne Lavallee
RMReza Mehrazin
Reza Mehrazin
JSJohn P. Sfakianos
John P. Sfakianos

22 April 2022 in Ophthalmology Glaucoma
Verified
Journal Article
Closed access
JHJeff J. Huang
Jeff J. Huang
JGJack E. Geduldig
Jack E. Geduldig
EJErica B. Jacobs
Erica B. Jacobs
TTTak Yee T. Tai
Tak Yee T. Tai
SASumayya Ahmad
Sumayya Ahmad
LPLouis Pasquale
Louis Pasquale

23 January 2025 in BJU International
Verified
Journal Article
Closed access
RBReuben Ben-David
Reuben Ben-David
FPFrancesco Pellegrino
Francesco Pellegrino
RMReza Mehrazin
Reza Mehrazin
JTJoel Thomas
Joel Thomas
JGJack Geduldig
Jack Geduldig
PWPeter Wiklund
Peter Wiklund

1 December 2020 in Neuro-Oncology
Verified
Journal Article
Open access
PDF file
BEBernhard Englinger
Bernhard Englinger
JGJohannes Gojo
Johannes Gojo
LJLi Jiang
Li Jiang
JHJens M Hübner
Jens M Hübner
MSMcKenzie L Shaw
McKenzie L Shaw
MFMariella Filbin
Mariella Filbin
Ependymoma represents a heterogeneous disease affecting the entire neuraxis. Extensive molecular profiling efforts have identified molecular ependymoma subgroups based on DNA methylation. However, the intratumoral heterogeneity and developmental origins of these groups are only partially understood, and effective treatments are still lacking for about 50% of patients with high-risk tumors. We interrogated the cellular architecture of ependymoma using single cell/nucleus RNA-sequencing to analyze 24 tumor specimens across major molecular subgroups and anatomic locations. We additionally analyzed ten patient-derived ependymoma cell models and two patient-derived xenografts (PDXs). Interestingly, we identified an analogous cellular hierarchy across all ependymoma groups, originating from undifferentiated neural stem cell-like populations towards different degrees of impaired differentiation states comprising neuronal precursor-like, astro-glial-like, and ependymal-like tumor cells. While prognostically favorable ependymoma groups predominantly harbored differentiated cell populations, aggressive groups were enriched for undifferentiated subpopulations. Projection of transcriptomic signatures onto an independent bulk RNA-seq cohort stratified patient survival even within known molecular groups, thus refining the prognostic power of DNA methylation-based profiling. Furthermore, we identified novel potentially druggable targets including IGF- and FGF-signaling within poorly prognostic transcriptional programs. Ependymoma-derived cell models/PDXs widely recapitulated the transcriptional programs identified within fresh tumors and are leveraged to validate identified target genes in functional follow-up analyses. Taken together, our analyses reveal a developmental hierarchy and transcriptomic context underlying the biologically and clinically distinct behavior of ependymoma groups. The newly characterized cellular states and underlying regulatory networks could serve as basis for future therapeutic target identification and reveal biomarkers for clinical trials.